Idorsia Ltd (SWX:IDIA)

Market Cap	800.41M
Revenue (ttm)	232.51M
Net Income (ttm)	-117.94M
Shares Out	249.74M
EPS (ttm)	-0.59
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	689,477
Average Volume	1,196,242
Open	3.160
Previous Close	3.150
Day's Range	3.130 - 3.250
52-Week Range	0.633 - 4.850
Beta	1.70
RSI	46.11
Earnings Date	Feb 26, 2026

About Idorsia

Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland, the United States, Japan, Europe, China, and Canada. The company has a clinical development pipeline for various therapeutic areas, such as CNS, cardiovascular, immunological disorders, and orphan diseases. It offers QUVIVIQ (daridorexant) for the treatment of insomnia. The company’s product pipeline includes Lucerastat, a glucosylceramide synthase inhibitor, which is in phase 3 clinical trial t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2017
• Employees: 650
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: IDIA

Financial Performance

In 2024, Idorsia's revenue was 112.51 million, a decrease of -26.17% compared to the previous year's 152.39 million. Losses were -263.76 million, -11.47% less than in 2023.